americanpharmaceuticalreviewMarch 11, 2020
Tag: Mylan Pharmaceuticals , Wixela Inhub , Advair Diskus
Mylan Pharmaceuticals announced the launch of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first available bioequivalent alternative to ADVAIR DISKUS in Canada. Wixela Inhub was approved by Health Canada in January for the twice daily maintenance treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma control medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta2-agonists; or maintenance treatment of COPD.
Wixela Inhub is available in the 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths for asthma patients and the 250 mcg/50 mcg and 500 mcg/50 mcg strengths for COPD patients.
"We're pleased to offer Wixela Inhub as the first available bioequivalent alternative to ADVAIR DISKUS, one of the leading treatments for asthma and COPD management today. Wixela Inhub is the result of a $700M investment worldwide, including an extensive research and development program. With today's launch in Canada, we are pleased to expand access to this important medicine by providing a more affordable alternative to appropriate asthma and COPD patients," Mylan Canada Country Manager David Simpson said.
The research and development program for Wixela Inhub compared all strengths of treatment to ADVAIR DISKUS in order to meet regulatory requirements of therapeutic equivalence for a substitutable generic. In the 28-day, randomized, double-blind, placebo-controlled, parallel group study of 1,122 adult asthma patients conducted to evaluate the local (lung) bioequivalence of Wixela Inhub 100 mcg/50 mcg and ADVAIR DISKUS 100 mcg/50 mcg, the two treatments produced equivalent efficacy. Both treatments were safe and well-tolerated with lower numbers of withdrawals due to asthma compared to the placebo group. The study included both naive and current users of ADVAIR DISKUS.
ADVAIR DISKUS had Canadian sales of $113.9 million for the 12 months ending December 31, 2019, according to IQVIA.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: